TBVAC-HORIZON held its second annual progress meeting
From 29 to 30 January 2025, the second annual progress meeting of TBVAC-HORIZON took place in Les Diablerets, Switzerland. All consortium partners presented the progress made in their research and development activities. The various work packages had lively seperate as well as joint consultations, which fostered very intense dynamic discussions and exchanges of progress and […]
Third call for applications to assess efficacy of Mycobacterium tuberculosis vaccine candidates
Diversifying the vaccine development pipeline has been recognized as a priority in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium has successfully secured funding for a four-year project that aims to fill the early stages of the development pipeline while ensuring a diverse portfolio of vaccine candidates (TBVAC-HORIZON – TBVI). One of the key […]
Mycobacterium tuberculosis vaccine candidates selected to assess efficacy in a mouse model
Following the call for vaccine researchers to submit their vaccine candidate for testing in a mouse model, we are delighted to announce the selection of three candidates. Based on predetermined criteria, the Portfolio Advisory Committee has selected candidates who are eligible to participate in the head-to-head comparison testing program within the TBVAC-HORIZON project. The assessment […]
Second call for applications to assess efficacy of Mycobacterium tuberculosis vaccine candidates in a mouse model
Diversification of the vaccine development pipeline has been identified as a priority area in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium aims, amongst other things, to fill the early phases of the development pipeline while ensuring a diverse portfolio (TBVAC-HORIZON – TBVI). One of the objectives of the project is to perform head-to-head […]
University of Oxford (UOXF) starts aligned clinical study – first participant enrolled
TBVAC-HORIZON has met an important milestone: On 3 April 2024, the first participant in the UOXF “TB46” study was enrolled. Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of TB infection by novel vaccines would provide the most cost-effective approach to achieve the goals of […]
TBVAC-HORIZON kicks off
The Horizon Europe programme has funded the TBVAC-HORIZON project to improve the understanding of lung immunity to tuberculosis infection and to establish a diversified innovative TB vaccine pipeline targeting mucosal immunity. TBVAC-HORIZON, consisting of 19 partners, will be coordinated by TBVI and will run for 4 years. To read more about the project, follow the […]